Evidence map›Paper›PMID 29948643›Full record

ArticleMolecular imaging and biology2019

SNAPshots of the MCHR1: a Comparison Between the PET-Tracers [

Cécile Philippe, Markus Zeilinger, Monika Dumanic, Florian Pichler, Lukas Fetty, Chrysoula Vraka, Theresa Balber, Wolfgang Wadsak, Katharina Pallitsch, Helmut Spreitzer and 3 more

Open access · hybridAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular imaging and biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Frontiers in endocrinology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Cécile PhilippeDepartment of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Markus ZeilingerDepartment of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Monika DumanicDepartment of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Florian PichlerDepartment of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Lukas FettyDepartment of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Chrysoula VrakaDepartment of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Theresa BalberDepartment of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Wolfgang WadsakDepartment of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Katharina PallitschDepartment of Organic Chemistry, University of Vienna, Vienna, Austria.
Helmut SpreitzerDepartment of Pharmaceutical Chemistry, University of Vienna, Vienna, Austria.
Rupert LanzenbergerDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.
Marcus HackerDepartment of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Markus MitterhauserDepartment of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. markus.mitterhauser@meduniwien.ac.at.ORCID http://orcid.org/0000-0003-3173-5272
Medical University of Vienna · ATUniversity of Vienna · ATFachhochschule Wiener Neustadt · AT

Funding

Austrian Science Fund FWF P 20977
6 · The paper itself

Abstract

purposeThe melanin-concentrating hormone receptor 1 (MCHR1) has become an important pharmacological target, since it may be involved in various diseases, such as diabetes, insulin resistance, and obesity. Hence, a suitable positron emission tomography radiotracer for the in vivo assessment of the MCHR1 pharmacology is imperative. The current paper contrasts the extensive in vitro, in vivo, and ex vivo assessments of the radiotracers [ PROCEDURES: Kinetic real-time cell-binding studies with [

results[

conclusionsBoth radiotracers demonstrate appropriate imaging properties for the MCHR1. However, the pronounced metabolic stability as well as superior selectivity and affinity of [

Indexed as

Positron-Emission TomographyAnimalsBlood ProteinsCarbon RadioisotopesCHO CellsChromatography, AffinityCricetinaeCricetulusFluorine RadioisotopesHumansKineticsMetabolomeMicePiperidinesProtein BindingPyrimidinesBlood ProteinsCarbon-11Carbon RadioisotopesFluorine-18Fluorine RadioisotopesMCHR1 protein, humanPiperidinesPyrimidinesReceptors, SomatostatinSNAP7941[11C]SNAP-7941[18F]FE@SNAPEx vivoIn vitroIn vivoMCHR1PETSmall animal imaging

Identifiers

PMID29948643
PMCPMC6449294
OpenAlexW2808603827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.